Genetic and epigenetic alterations in exceptional benefit (left) and short-term (right) subgroup patients in the rucaparib arm. BL, baseline; BR, best response; BRCA, BRCA1 or BRCA2; CT, chemotherapy; HRD, homologous recombination deficiency; HRR, homologous recombination repair; LOH, loss of heterozygosity; plt, platinum; PPFI, penultimate platinum-free interval.